PE20071099A1 - Inmunoglobulinas en el tratamiento de enfermedades neurologicas - Google Patents

Inmunoglobulinas en el tratamiento de enfermedades neurologicas

Info

Publication number
PE20071099A1
PE20071099A1 PE2006001607A PE2006001607A PE20071099A1 PE 20071099 A1 PE20071099 A1 PE 20071099A1 PE 2006001607 A PE2006001607 A PE 2006001607A PE 2006001607 A PE2006001607 A PE 2006001607A PE 20071099 A1 PE20071099 A1 PE 20071099A1
Authority
PE
Peru
Prior art keywords
seq
treatment
neurological diseases
immunoglobulins
l16fl
Prior art date
Application number
PE2006001607A
Other languages
English (en)
Inventor
Stephanie Jane Clegg
Jonathan Henry Welbore Ellis
Volker Germaschewski
Paul Andrew Hamblin
Ruth Anne Mcadam
George Kopsidas
Rabinder Kumar Prinjha
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35736284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20071099(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20071099A1 publication Critical patent/PE20071099A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

SE REFIERE A UN ANTICUERPO AISLADO HUMANIZADO QUE COMPRENDE UNA REGION VARIABLE DE CADENA PESADA QUE TIENE LA SECUENCIA DE AMINOACIDOS DADA EN SEC ID N 47(H26), SEC ID N 48(H27), SEC ID N(H28), SEC ID N 63(H100), SEC ID N 65(H102) Y UNA REGION VARIABLE DE CADENA LIGERA. DICHO ANTICUERPO COMPRENDE LAS SIGUIENTES SECUENCIAS DE CADENAS PESADAS Y LIGERAS: H27FL L16FL (SEC ID N 54 + SEC ID N 18), H28FL L13FL (SEC ID N 55 + SEC ID 17), H28FL L16FL (SEC ID N55 + SEC ID N 18), ES CAPAZ DE UNIRSE A UNA REGION DE LA PROTEINA NOGO HUMANA UTIL EN EL TRATAMIENTO O PROFILAXIS DE APOPLEJIA Y OTRAS ENFERMEDADES NEUROLOGICAS
PE2006001607A 2005-12-16 2006-12-14 Inmunoglobulinas en el tratamiento de enfermedades neurologicas PE20071099A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0525662.3A GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins

Publications (1)

Publication Number Publication Date
PE20071099A1 true PE20071099A1 (es) 2007-11-22

Family

ID=35736284

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001607A PE20071099A1 (es) 2005-12-16 2006-12-14 Inmunoglobulinas en el tratamiento de enfermedades neurologicas

Country Status (31)

Country Link
US (2) US8362208B2 (es)
EP (2) EP2228391A3 (es)
JP (1) JP5015949B2 (es)
KR (1) KR101355118B1 (es)
CN (1) CN101374863B (es)
AR (1) AR057239A1 (es)
AU (1) AU2006325228B2 (es)
BR (1) BRPI0619855A2 (es)
CA (1) CA2633501C (es)
CR (1) CR10099A (es)
CY (1) CY1113094T1 (es)
DK (1) DK1960429T3 (es)
EA (1) EA015536B1 (es)
ES (1) ES2389380T3 (es)
GB (1) GB0525662D0 (es)
HK (1) HK1119720A1 (es)
HR (1) HRP20120684T1 (es)
IL (1) IL192086A0 (es)
JO (1) JO2795B1 (es)
MA (1) MA30041B1 (es)
MY (1) MY149492A (es)
NO (1) NO20082699L (es)
NZ (1) NZ569143A (es)
PE (1) PE20071099A1 (es)
PL (1) PL1960429T3 (es)
PT (1) PT1960429E (es)
SI (1) SI1960429T1 (es)
TW (1) TWI378940B (es)
UA (1) UA96279C2 (es)
WO (1) WO2007068750A2 (es)
ZA (2) ZA200805111B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2425768T3 (es) * 2007-11-02 2013-10-17 Novartis Ag Moléculas de unión a nogo-a mejoradas y uso farmacéutico de las mismas
ES2654937T3 (es) 2008-04-02 2018-02-15 Macrogenics, Inc. Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
TW201012490A (en) 2008-05-06 2010-04-01 Glaxo Group Ltd Encapsulation of biologically active agents
JP2011527317A (ja) * 2008-07-11 2011-10-27 グラクソ グループ リミテッド Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
AU2013285493A1 (en) 2012-07-05 2015-01-22 Glaxo Group Limited Optimum dose regime of an anti-Nogo-A antibody in the treatment of amyotrophic lateral sclerosis
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
US11013815B2 (en) 2017-06-14 2021-05-25 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
US20230399390A1 (en) 2019-10-24 2023-12-14 Novago Therapeutics Ag Novel anti-nogo-a antibodies
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
WO2022263864A1 (en) 2021-06-17 2022-12-22 Petmedix Ltd Anti canine cd20 antibodies
WO2023067358A1 (en) 2021-10-21 2023-04-27 Petmedix Ltd Proteins comprising the extracellular domain of p75ntr
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
WO2023152486A1 (en) 2022-02-09 2023-08-17 Petmedix Ltd Therapeutic antibodies
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
NZ287442A (en) 1994-05-27 1998-05-27 Smithkline Beecham Spa 4-substituted quinoline derivatives; medicaments; use as an nk3 receptor antagonist
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
DE69633336T2 (de) 1995-06-27 2005-09-22 Research Foundation Of Cuny Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
DK1098972T3 (da) 1998-07-22 2011-01-03 Smithkline Beecham Ltd Protein med lighed med neuroendokrinspecifikt protein samt cDNA kodende derfor
AU774367C (en) 1998-11-06 2005-04-21 University Of Zurich Nucleotide and protein sequences of nogo genes and methods based thereon
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
DE10338136A1 (de) 2003-08-15 2005-03-24 European Molecular Biology Laboratory Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
WO2005061544A2 (en) * 2003-12-22 2005-07-07 Glaxo Group Limited Nogo-a neutralising immunoglobulins for treatment of neurological diseases
AU2005207003C1 (en) * 2004-01-20 2013-06-13 Humanigen, Inc. Antibody specificity transfer using minimal essential binding determinants
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor

Also Published As

Publication number Publication date
WO2007068750A2 (en) 2007-06-21
KR101355118B1 (ko) 2014-02-06
EP1960429B1 (en) 2012-06-27
HK1119720A1 (en) 2009-03-13
ZA200805111B (en) 2009-12-30
UA96279C2 (ru) 2011-10-25
GB0525662D0 (en) 2006-01-25
US20130287781A1 (en) 2013-10-31
US20100221260A1 (en) 2010-09-02
AU2006325228B2 (en) 2011-12-15
KR20080080644A (ko) 2008-09-04
ES2389380T3 (es) 2012-10-25
CA2633501C (en) 2015-03-31
PT1960429E (pt) 2012-09-25
NZ569143A (en) 2011-08-26
ZA200906162B (en) 2010-05-26
TW200801038A (en) 2008-01-01
CN101374863B (zh) 2013-05-29
WO2007068750A3 (en) 2007-11-29
JP5015949B2 (ja) 2012-09-05
PL1960429T3 (pl) 2012-11-30
CY1113094T1 (el) 2016-04-13
BRPI0619855A2 (pt) 2011-10-25
AR057239A1 (es) 2007-11-21
NO20082699L (no) 2008-09-08
IL192086A0 (en) 2008-12-29
DK1960429T3 (da) 2012-09-24
CR10099A (es) 2008-09-22
EP2228391A2 (en) 2010-09-15
JO2795B1 (en) 2014-03-15
MY149492A (en) 2013-09-13
EP1960429A2 (en) 2008-08-27
CA2633501A1 (en) 2007-06-21
TWI378940B (en) 2012-12-11
US8362208B2 (en) 2013-01-29
CN101374863A (zh) 2009-02-25
MA30041B1 (fr) 2008-12-01
EP2228391A3 (en) 2010-12-29
EA015536B1 (ru) 2011-08-30
SI1960429T1 (sl) 2012-09-28
HRP20120684T1 (hr) 2012-09-30
JP2009519025A (ja) 2009-05-14
AU2006325228A1 (en) 2007-06-21
EA200801343A1 (ru) 2008-12-30

Similar Documents

Publication Publication Date Title
PE20071099A1 (es) Inmunoglobulinas en el tratamiento de enfermedades neurologicas
RU2505603C2 (ru) Антитело против рецептора il-6
PE20190212A1 (es) Anticuerpos anti_ige
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
BR112019011988A2 (pt) anticorpo anti-cd73 humana
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
CO2019007844A2 (es) Anticuerpo anti-receptor de transferrina humana novedoso capaz de penetrar la barrera hematoencefálica
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
PE20120343A1 (es) Anticuerpo anti-cmet que comprende una region bisagra
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
PE20121034A1 (es) Anticuerpos anti-factor d humanizados
AR075790A2 (es) Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural)
PE20211863A1 (es) Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
PE20190737A1 (es) Anticuerpos anti-cd27
PE20081478A1 (es) Anticuerpos cd44
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
CO6180467A2 (es) Moleculas de anticuerpo que unen il -17 e il- 17 f
PE20171512A1 (es) Anticuerpos anti-fap
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
ES2570853T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
CO6231009A2 (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
PE20141548A1 (es) Anticuerpo anti-alfabeta tcr
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
PE20200695A1 (es) Anticuerpos que reconocen tau

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed